PerspectiveHuman Genome Anniversary

For better drugs, diversify clinical trials

See allHide authors and affiliations

Science  05 Feb 2021:
Vol. 371, Issue 6529, pp. 570-571
DOI: 10.1126/science.abe2565

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

COVID-19 has highlighted the devastating disparities that exist for Black, Latinx, and Indigenous people in health care and medicine in the United States and other parts of the world. As a result, the importance of ethnic diversity in clinical trials has entered public discourse. This moral issue is enough to warrant elevation. But there are also scientific considerations because a lack of diversity in clinical trials hinders the ability to fully understand variation and predict drug outcomes across populations, including those most hard-hit by a disease.

View Full Text

Stay Connected to Science